A nonalcoholic fatty liver disease cirrhosis model in gerbil
Li, Wei; Guan, Zheng; Brisset, Jean C.; Shi, Qiaojuan; Lou, Qi; Ma, Yue; Suriguga, Su; Ying, Huazhong; Sa, Xiaoying; Chen, Zhenwen

Published in:
International Journal of Clinical and Experimental Pathology

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2018

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
Original Article
A nonalcoholic fatty liver disease cirrhosis model in gerbil: the dynamic relationship between hepatic lipid metabolism and cirrhosis

Wei Li1,2, Zheng Guan3, Jean C Brisset6, Qiaojuan Shi2, Qi Lou2, Yue Ma2, Su Suriguga4, Huazhong Ying2, Xiaoying Sa2, Zhenwen Chen5, Wim J Quax3, Xiaofeng Chu2

1Laboratory Animal Center, Zhejiang University, Hangzhou, Zhejiang, China; 2Laboratory Animal Center, Zhejiang Academy of Medical Sciences, Hangzhou, Zhejiang, China; Departments of 3Chemical and Pharmaceutical Biology, 4Pharmaceutical Technology and Biopharmacy, GUIDE, University of Groningen, Groningen, The Netherlands; 5Department of Laboratory Animal Science, School of Basic Medical Science, Capital Medical University, Beijing, China; 6Department of Radiology, New York University, New York, State of New York, The United States

Received November 2, 2017; Accepted November 21, 2017; Epub January 1, 2018; Published January 15, 2018

Abstract: Nonalcoholic fatty liver disease (NAFLD) usually takes decades to develop into cirrhosis, which limits the longitudinal study of NAFLD. This work aims at developing a NAFLD-caused cirrhosis model in gerbil and examining the dynamic relationship between hepatic lipid metabolism and cirrhosis. We fed gerbil a high-fat and high-cholesterol diet (HFHCD) for 24 weeks, and recorded the gerbil’s phenotype at 3, 6, 9, 12, 15, 18, 21, 24 weeks. The model’s pathological process, lipid metabolism, oxidative stress, liver collagen deposition and presence of relevant cytokines were tested and evaluated during the full-time frame of disease onset. The gerbil model can induce non-alcoholic steatohepatitis (NASH) within 9 weeks, and can develop cirrhosis after 21 weeks induction. The model’s lipids metabolism disorder is accompanied with the liver damage development. During the NAFLD progression, triglycerides (TG) and free fatty acids (FFA) have presented distinct rise and fall tendency, and the turning points are at the fibrosis stage. Besides that, the ratios of total cholesterol (CHO) to high-density lipoprotein cholesterol (HDL-C) exhibited constant growth tendency, and have a good linear relationship with hepatic stellate cells (HSC) ($R^2 = 0.802$, $P < 0.001$). The gerbil NAFLD cirrhosis model has been developed and possesses positive correlation between lipids metabolism and cirrhosis. The compelling rise and fall tendency of TG and FFA indicated that the fibrosis progression can lead to impairment in lipoprotein synthesis and engender decreased TG level. CHO/HDL-C ratios can imply the fibrosis progress and be used as a blood indicator for disease prediction and prevention.

Keywords: Cirrhosis, fibrosis, hepatic lipid metabolism, nonalcoholic fatty liver disease (NAFLD), gerbil

Introduction
Cirrhosis is a severe stage of liver dysfunction and is most commonly caused by alcohol, viral hepatitis, and NAFLD. Since NAFLD has become a leading health problem worldwide, especially for those people who are living with obesity [1], the lack of a suitable animal model for NAFLD-caused cirrhosis has aroused more and more attention. It has been suggested that 20% of the adult population in the world now has NAFLD [2], with an increase of 90% morbidity in obese populations [3]. The whole natural history of NAFLD has four stages: simple steatosis, NASH, fibrosis and cirrhosis. Fibrosis can lead to an increased morbidity rate from cirrhosis, hepatic failure, metabolic syndrome associated cardiovascular and cerebrovascular diseases, and hepatic carcinoma [4]. The clinical progression from simple steatosis to cirrhosis of NAFLD usually takes decades, strongly impacting the NAFLD-caused cirrhosis mechanism research and related drug development. For this reason, finding a suitable animal model for NAFLD-caused cirrhosis study becomes crucial.

Currently, NAFLD animal models can be divided into two types, one is the genetic model, and the other one is a drug and/or diet-induced
Nonalcoholic fatty liver disease cirrhosis model in gerbil

Most commonly used genetic models are related to lipid metabolism genes, such as ob/ob mouse, db/db mouse, (fa/fa) Zucker rats, PPARα/− mouse, and PNPLA3 transgenic mouse. Whereas, spontaneous mutations are very rare in the clinic, and normally those cases are based on multiple gene mutations, which causes differences between clinic and the genetic models. For those drug and/or diet-induced models, the typical diets used to induce NAFLD are methionine choline deficient (MCD) diet [5, 6], high-fat diet (HFD, including high-fat and high-fat, high-cholesterol diets), and high-carbohydrate diet (HCD) [7]. Compared with the diet of human the MCD diet is abnormal, but HFD and HCD are similar. Additionally, comparing with the other animal models, our literature searches show that the rat HFD model is the more widely used model to investigate the etiology and pathogenesis of NAFLD [8-10]. However, this type of model cannot induce cirrhosis [11, 12]. The induced animal can reach NASH stage and fibrosis stage, but the fibrosis is mild and unstable. So in the past decade, a great emphasis has been placed on the animal models for NAFLD study.

The Mongolian gerbil (*Merionesunguiculatus*) is a fat-sensitive animal [13-18]. Its plasma lipid response to dietary fatty acids is more sensitive than humans, even without dietary cholesterol [13-18]. Due to its reported lipemic responses to dietary fat and cholesterol [13-20], the gerbil has been chosen to establish NAFLD animal model. Moreover, previous research findings have pointed out that NASH is associated with metabolic syndrome [21-25], and gerbil has the tendency to acquire diabetes spontaneously [26]. We attempt to establish a stable animal model, which shares the major clinical pathogenic factors: HFD, male, and lipid metabolism disorder [2]. Since we have clearly observed fibrosis stage and verified the stability of a gerbil NASH model in our former work [27, 28], the gerbil NASH model was used for developing a NAFLD-caused cirrhosis model and studying the mechanism. This is the first study to undertake a longitudinal observation of the whole natural history of NAFLD in gerbil and to investigate the dynamic relationship between hepatic lipid metabolism and cirrhosis. This is also the first comprehensive description of the new established NAFLD-caused cirrhosis model. The model's pathological process, lipid metabolism, oxidative stress, liver collagen deposition and related cytokines were examined and evaluated in this research.

**Methods**

**Animals**

A total of 72 male littermate Mongolian gerbils (*Merionesunguiculatus*) were obtained from Zhejiang Academy of Medical Sciences, Zhejiang Center of Laboratory Animals (Hangzhou, China). All experiments were performed in accordance to the guidelines for animal care and use of Zhejiang province and Zhejiang Academy of Medical Sciences, and approved by the Ethics Committee of Zhejiang Academy of Medical Sciences (No. SCXK (Zhe) 2008-0033, and No. SYXK (Zhe) 2008-0113).

**HFHCD for induction of NAFLD and cirrhosis**

Gerbils were divided randomly into nine groups: one control group (n = 8) and eight time point model groups (each group, n = 8). The control group animals were fed a normal diet for 24 weeks, while the model group animals were fed an HFHCD. Based on former reports [29], we developed a new diet recipe (China Patent No. CN 102106476 A) to establish the model, which is similar to the western diet and containing the following components: 10% egg yolk powder (Zhejiang Changxing Ags Biological Products Co., Ltd.), 7% lard oil (purchased from local supermarket), 2.5% cholesterol (Huadong Pharmaceutical Co., Ltd) and 0.2% cholate (Huadong Pharmaceutical Co., Ltd). The nutritional differences of the diets are shown in [Supplementary Table 1](#).}

**Experimental design**

Every eight model animals were sacrificed at the end of week 3, 6, 9, 12, 15, 18, 21 and 24 for dynamic pathological and mechanical studies. Eight control animals were spared at the end of week 24. Blood samples were collected from abdominal aorta [30], allowed to clot for 2 hours at room temperature, centrifuged (3,500 × g, 10 min), and the supernatant was used for measurement of alanine transaminase (ALT), aspartate transaminase (AST), CHO, TG, HDL-C, low density lipoprotein choles-
terol (LDL-C) and glucose (GLU). Liver samples were obtained from the central part of the largest liver lobe. Liver homogenate was prepared to determine the content of FFA; and the following fibrosis indexes: type I collagen, type III collagen, transforming growth factor \( \beta_1 \) (TGF-\( \beta_1 \)), and platelet-derived growth factor (PDGF), which were examined by western blotting (see Supplementary). Another part of the liver sample was fixed by 10% formalin and embedded in paraffin for histological study, and then were stained with hematoxylin and eosin (HE) and with Masson trichrome (for collagen). Besides, liver biopsy specimens were also immunohistochemically examined for Kupffer cells by assessing the expression of the receptor CD68, and HSC by evaluating the activation of the marker of HSC: alpha-smooth muscle actin (\( \alpha \)SMA). As a double check, type I collagen and type III collagen were appraised as well as Kupffer cells and HSC by immunohistochemical examination. Meanwhile, for lipid accumulation assessment, electron microscope was employed to observe the liver tissue.

**Biochemical analysis**

The levels of serum ALT, AST, CHO, TG, GLU, LDL-C, and HDL-C were determined by an automatic chemical analyzer (HITACHI 7100, Japan). Commercial kits (Huifeng Science & Technology Co. Ltd., Shanghai, China; Jiancheng Biotech. Sci. Inc., Nanjing, China) were used for these analysis. All the procedures were followed as those stated in the protocols of the detection kits. Likewise, the levels of FFA in liver were examined by a Nonesterified free fatty acids assay kit (Jiancheng Biotech. Sci. Inc., Nanjing, China).

**Histopathology, electron microscope observation and immunohistochemical analysis**

For histopathological study, the liver sections were stained with HE and with Masson's trichrome. Histological steatosis, inflammation, and fibrosis were assessed semiquantitatively by a single-blinded pathologist, according to the scoring system proposed by Kleiner et al. [31]. During the assessment, a Leica microscope (Leica DM2500, Germany) was used for the observation. In each liver section, images of 10 random fields were taken (10 × 2.5 original magnification; 0.22 mm\(^2\) total area per image) for the judgment.

For transmission electron microscope observation, one animal was selected randomly from each group. After the liver was washed by using 0.9% physiological saline, a piece of the hepatic tissue was cut off from the central part of the largest liver lobe (about 1 × 1 × 1 mm). And then, the tissue was fixed in 2.5% glutaraldehyde for 4 hours at 4°C. Later, the samples were sent to electron microscopic laboratory (Virus Research Institute, Chinese Academy of Sciences), to gain the transmission electron microscope result.

The Kupffer cell, hepatic stellate cell, type I collagen, and type III collagen were detected using the common immunohistochemical method (see Supplementary). In order to show the fibrosis progression during the HFHCD induction clearly, an improved German immunohistochemical scoring (GIS) system [32] was employed to access the immunohistochemical slices. The percentage of positive cells was graded as follows: 0, negative; 1, up to 10% positive cells; 2, 11% to 20%; 3, 21% to 30%; 4, 31% to 40%; 5, 41% to 50%; 6, 51% to 60%; 7, 61% to 70%; 8, 71% to 80%; and 9, > 80%. The intensity of marker expression was graded as follows: 0, negative; 1, weakly positive; 2, moderately positive; 3, strongly positive. The final immunoreactive score equals to the product of the percentage of positive cells multiply the highest staining intensity.

**Statistical analysis**

Data are presented as the mean ± SD and compared by analysis of variance after validation of homoscedasticity using Bartlett's chi-square test. Statistical comparisons were carried out using the SPSS Statistics 19 system (IBM Corporation, Armonk, New York, USA) and freely available R programming language (v 3.2.5). The R package “scatterplot3d”, “lmtest”, “psych”, “ggm”, “car”, “psy”, and “ggplot2” were used in this study. The data set distribution was closer to a normal distribution. Then, a two-sample, two-sided t-test was applied to determine the significance of the differences between model group and the corresponding control group. The acceptable level of statistical significance was set at \( P < 0.05 \).
Nonalcoholic fatty liver disease cirrhosis model in gerbil

Results

Histological and biochemical assessment of HFHCD induced NAFLD and cirrhosis

In the morphological observations, the control group gerbils have shown soft livers with normal color and smooth surfaces, whereas the model group gerbils presented different degrees of pathological liver over time. The liver of model group animals became swollen and hard and turned pale yellow, the edge of the pathological liver developed into a blunt shape, and the liver surface changed into an irregular pattern with whitish micronodules and macronodules (Figure 1F), which indicated the liver damage changes over the HFHCD induction time.

The comparison of histopathological study of the model group and control group has also shown a similar tendency as morphology observation. As exhibited in Figure 1A, no discernible histological alterations could be identified in control group. They had complete cytoplasm, sinusoidal spaces, distinct nucleus, nucleolus and central vein. In contrast, the model group presented a full blown cirrhosis feature accompanied with steatosis (Figure 1E), and a significantly higher fibrosis score (Supplementary Table 2). These results provided microscopic evidence that indicated the significant liver damage changes over the HFHCD induction time. The independent pathological judgment [31] (Supplementary Table 2) show the obvious steatosis stage (Figure 1B) between 3 to 6 weeks, the NASH stage (Figure 1C, 1D) between 9 to 18 weeks, and liver fibrosis stage (Figure 1D) after 12 weeks HFHCD induction. Finally, the cirrhosis model (Figure 1E, 1F) can be seen to have been established after 21 weeks HFHCD induction (Figure 2).

Supplementary Tables 3 and 4 presented the results of raised ALT, AST, GLU, TG, CHO and body weight of model animals (0-9 weeks). These results exhibited the well repeated gerbil NASH model as we have reported before [27, 28].

In accord with the pathological assessment and transaminases results, in comparison to the control group, the immunohistochemical analysis and western blot results also show a compelling increase of type I ($P < 0.05$, after 21 weeks) and type III collagens ($P < 0.01$, after 15 weeks) in the model group (Figure 3). As shown in Figure 3B, After 15 weeks of HFHCD
Nonalcoholic fatty liver disease cirrhosis model in gerbil

induction, collagen III was increasing consistently ($P < 0.001$); on the other hand, collagen I was significantly increased again at week 24 ($P < 0.01$). Both of the type I and type III collagens reached the biochemical peak at week 24, which strengthen the assurance of the model.

Activation of Kupffer cell and HSC

Kupffer cells and hepatic stellate cells are generally regarded as keys of the fibrosis and cirrhosis mechanisms. In this study, Kupffer cells and hepatic stellate cells were evaluated by assessing the expression of the receptor CD-68, and αSMA, the marker of activated HSC. As expected, the control group animals only have few Kupffer cells, and no activated HSC has been observed (Figure 3). Whereas, the model groups show many Kupffer cells and HSC (Figure 3) after 12 weeks of HFHCD induction. Compare with the control group, the increase of Kupffer cells after 12 weeks HFHCD induction is significant: 12 weeks, $P < 0.01$; 15 weeks, $P < 0.05$; 18 weeks, $P < 0.01$; 21 weeks, $P < 0.001$; and 24 weeks, $P < 0.001$.

The correlation coefficient between the other variables and HSC measurements were calculated to be 0.68 for TGF-β1, 0.41 for PDGF and 0.62 for Kupffer cell (Figure 4B). The strong positive correlation between those chronic inflammation factors and HSC implies that the HFHCD induced cirrhosis may be partly caused by the chronic inflammation factors [11, 33], which directly induced the activation of HSC. Besides that, partial correlation analysis shows that TGF-β1 has a strong positivecorrelation with HSC, its partial correlation coefficient is 0.65, which is similar to their correlation coefficient mentioned above (0.68, TGF-β1 and HSC). This result suggests that TGF-β1 and HSC has a strong and direct positive correlation. The followed-up statistical analysis also indicates TGF-β1 is prior to HSC and is the Granger-cause of HSC ($P < 0.05$, optimal lagorder is determined by Akaike information criteria) [34, 35]. Since TGF-β1 is the Granger-cause of HSC, along with HFHCD feeding time, we calculated their linear regression formula: $HSC = 2.467 + 1.279e^{-5} \times TGF-\beta1 + 1.831e^{-1} \times Time$ ($R^2 = 0.764$, TGF-β1 is based on the gray scale values of western blotting result [36]) (Figure 4B), and their coefficients are significant ($P < 0.001$). Its good linear relation offers TGF-β1 as a new supplement indicator for fibrosis diagnosis and prediction.

Dynamic relationship between hepatic lipid metabolism and cirrhosis

The lipid accumulation in liver was observed by transmission electron microscopy. The ul-
trastructure of hepatic cells was normal in control group: the membrane was well defined; chromatin was uniformly distributed. No fat droplet could be found in mitochondria, endoplasmic reticulum or liver cell. The cell nucleus was overall in shape (Figure 5A). In contrast, the model group animals have many fat droplets and formation of vacuoles in liver cells. After 3 weeks HFHCD induction, the small lipid droplets appeared everywhere in the cell (Figure 5B, 5C). And then, during the HFHCD induction process, the fat droplets accumulated into some big lipid droplets (Figure 5E, 5F). The observed lipid accumulation changes indicated the severity degree of hepatic lipid metabolism disorder, which also complies with the NAFLD progression. In addition, total CHO, LDL-C, FFA and HDL-C were increased dramatically in relation to the HFHCD induction time (Figures 5D and 4A). To illustrate the dynamic relationship between hepatic lipid metabolism and cirrhosis, a focused principal components analysis (FPCA) has been performed [37]. Since TG and FFA have shown distinct rise and fall tendency, and the turning point is at 18 weeks and 12 weeks (fibrosis stage). Accordingly, FPCA also reflected the differences. The analysis has shown significant positive correlation between HSC and all the tested factors ($P < 0.05$), except FFA and TG (Figure 4B). FPCA revealed that HDL-C, LDL-C, and CHO belong to the main factors in this experiment, and their increment can promote the fibrosis progression (Figure 4B).
Discussion

Our novel data shows that in the first 9 weeks HFHCD induction, the model’s body weight, GLU, ALT, AST, CHO, and TG levels were significantly increased (Supplementary Tables 3 and 4). The histological scoring system also shows the NASH features. Therefore, the gerbil NASH model has been repeated well as our former studies [27, 28]. During the whole study period, a number of features in common with human disease were found: (i) the excessive accumulation of FFA, (ii) blood lipid metabolism disorder, (iii) cellular ballooning, (iv) immunohistochemistry changes, and (v) liver morphology modifications [38-40]. Progression of the cirrhosis from NAFLD was clearly subdivided into stages (Figure 2) allowing the study of the progression of the disease and the correlation with the HFHCD induction time. The result indicates a strong positive correlation between lipids metabolism and cirrhosis, which mimics the clinical disease. Therefore, the gerbil NAFLD cirrhosis model has been established and can be used to study NAFLD progression, especially the cirrhosis stage, for a better understanding of the disease pathophysiology and for medicine development.

Besides, during the longitudinal study we have observed a distinct rise and fall tendency of TG and FFA levels, and their turning points are...
in the fibrosis stage. The decreased TG level seems rare based on our knowledge. Coincidentally, a Harvard group has also reported the similar tendency recently [41]. Their clinical study statistically analyzed 11947 cases, and pointed out that lower triglyceride levels may indicate more advanced liver disease. The fibrosis progression caused liver dysfunction can possibly lead to resultant impairment in lipoprotein synthesis and result in decreased triglyceride export. The accompanied FFA level changes are the support of the inference.

Since the gerbil NAFLD cirrhosis model has been well developed, which not only possess the similar clinical features but also can be clearly divided into stages, we tried FPCA to find out the closest indexes of HSC for the dynamic monitoring and disease progression prognosis. The FPCA [37] result indicated that HDL-C, LDL-C, and CHO are closely related with HSC and other fibrosis indicators in the NAFLD-cirrhosis progression. The similar increasing tendency of Kupffer cells, HSC, TGF-β1, and PDGF also supports previous research into this area which indicated that the Kupffer cells can secrete TGF-β1, and PDGF to stimulate fibrosis development through the mitogenic stimuli of them on HSC [42]. Surprisingly, the growth of HDL-C was found abnormal during the HFHCD induction time, which has aroused our attention. In this study, HDL-C not only has strong positive correlation with HSC (r = 0.556, P < 0.05), but also has a good linear relationship with HSC along with the HFHCD induction time (Figure 4B, HSC = 1.047 + 0.756 × HDL-C + 0.178 × Time, R² = 0.823, P < 0.001). A few NAFLD studies [43, 44] have also reported the same HDL-C increase tendency, which may suggest the special mechanism during the NAFLD-caused fibrosis progression. So we looked into the CHO/HDL-C ratio to further inspect the model. It is interesting to note that the CHO/HDL-C ratios show constant growth tendency during the HFHCD induction, and have good linear relationship with HSC (HSC = 3.542 - 0.655 × CHO/HDL-C + 0.237 × Time, R² = 0.802, P < 0.001). These results are dramatically consistent with the clinic reports [45, 46] and may imply the special status of HDL-C in the NAFLD progression. Considering the possible HFD or HFHCD differences, environment differences, and animal differences in other labs, we suggest using CHO/HDL-C ratio as a convenient blood indicator for the standard gerbil model assessment. For this
purposes, the blood sample can be collected from the tail vein or the cheek vein (300 μL blood is enough for detecting more than two indexes), and the regression equation might be used to determine the NAFLD stage and suitable experiment time.

As we presented in the result, the pros and cons of this gerbil NAFLD cirrhosis model can easily be listed. First of all, this gerbil model can induce NASH within 9 weeks, and can develop stable cirrhosis after 21 weeks HFH-CD induction. This is in contrast to, as Robert Schierwagen reported, most of the existing HFD induced NAFLD models that need a minimum of 15 weeks induction and that hardly show stable fibrosis. Secondly, the model has the same fibrosis progression (e.g., HSC activation, collagen III and collagen I deposition, bridging fibrosis, and cirrhosis) as in the clinic, and leads to a stable cirrhosis stage. It can thus be suggested that the gerbil model can cover the whole NAFLD disease spectrum to make up the NAFLD model deficiency. Having the same features and etiologies as the clinical process combined with its stable cirrhosis stage, is key advantage of this gerbil model for the NAFLD and cirrhosis investigations. As still remaining limitations of the gerbil model we can mention that the additional diet cholesterol may cause some metabolism differences. Further studies are required to address whether alterations in diet composition can lead to a refined model, which can completely reproduce the human disease mechanism. Besides that, the 21 weeks cirrhosis induction time is still not very convenient. If the research purpose is only to study the cirrhosis stage, it would be meaningful to further improve the HFHCD recipe for the gerbil model.

In summary, we have firstly established a gerbil NAFLD cirrhosis model, which has stable fibrosis stage and can be used for NAFLD longitudinal study. The study shows for the first time that the lipids metabolism disorder is accompanied with liver damage during the whole NAFLD progression, and they have a positive correlation along with the HFHCD induction time. The dynamic observation also initially detected the noticeable rise and fall tendency of TG and FFA levels during the NAFLD progression. Moreover, the good linear relationship between CHO/HDL-C and HSC pioneered that the CHO/HDL-C ratio can be a convenient biomarker for the NAFLD progression judgment, especially for the fibrosis progression diagnosis and prediction.

Acknowledgements

The work is supported by National Sci-Tech Support Plan of China (2015BAI09B01-02). W.L. is supported by the Zhejiang Natural Science Foundation (LQ16H030003). Z.G. is supported by the China Scholarship Council (201408330157). We thank Honggang Guo and Lingqun Lu from Laboratory Animal Center, Zhejiang Academy of Medical Sciences, for their skilled technical assistance. We also want to thank Yafeng Song from Department of Chemical and Pharmaceutical Biology, University of Groningen for the proof reading.

Disclosure of conflict of interest

None.

Address correspondence to: Dr. Zhenwen Chen, Department of Laboratory Animal Science, School of Basic Medical Science, Capital Medical University, Beijing 100069, China. Tel: +86 10 83911495; E-mail: czwen@ccmu.edu.cn; Dr. Wim J Quax, Department of Chemical and Pharmaceutical Biology, GUIDE, University of Groningen, Groningen, 9713 AV, The Netherlands. Tel: +31 503632558; Fax: +31 503633000; E-mail: w.j.quax@rug.nl; Dr. Xiaofeng Chu, Laboratory Animal Center, Zhejiang Academy of Medical Sciences, Hangzhou 310013, Zhejiang, China. Tel: +86 571 86952350; Fax: +86 571 88208070; E-mail: sydw@zjinfo.gov.cn

References


Nonalcoholic fatty liver disease cirrhosis model in gerbil


Nonalcoholic fatty liver disease cirrhosis model in gerbil


Nonalcoholic fatty liver disease cirrhosis model in gerbil


Supplementary materials & methods: western blot, immunohistochemical method

Western blot: type I collagen, type III collagen, TGF-β1, and PDGF

Hepatic cells were lysed in RIPA lysis buffer (Beyotime Biotechnology, Jiangsu, China) with 1 mM phenylmethylsulphonyl fluoride (PMSF) (Amresco, Solon, OH, USA). After the samples were centrifuged at 10000 g for 5 minutes, protein levels in the supernatants were measured by a BCA assay kit (Beyotime Biotechnology, Jiangsu, China). For each sample, 50 µg of protein was separated on 10% polyacrylamide electrophoresis (160 V, 2 h), and transferred to a polyvinylidenedifluoride membrane (400 mA, 2 h at 4°C). The membranes were preblocked (1 h at room temperature) with 5% skimmed milk in Tris-buffered saline-Tween-20. Subsequently, membranes were incubated overnight at 4°C with the primary antibodies: anti-Collagen I, anti-Collagen III, anti-TGFβ1, and anti-PDGF (Abcam, Cambridge, MA, USA). After wash three times, the membranes were incubated with secondary antibodies HRP-labeled goat anti-rabbit IgG (H + L) (Beyotime Biotechnology, Jiangsu, China) (1:5000) for 1 hour and followed by another three washes for preparing the visualization. Finally, the results were visualized with enhanced chemiluminescence (ECL, Millipore, Billerica, MA), and were quantitative analyzed by using a BioshineChemiQ 4600 mini chemiluminescence imaging system (Bioshine, Shanghai, China).

Immunohistochemical method: Kupffer cell, hepatic stellate cell, type I collagen, and type III collagen

After the liver sections were dewaxed in xylene and graded alcohols, the sections were hydrated and washed in phosphate-buffered saline. Afterwards, the peroxidase in the sample was inhibited by 3% H₂O₂ for 10 minutes, and then the sections were pretreated in a pressure cooker in sodium citrate buffer, followed by an incubation step with 5% bull serum albumin for 30 minutes to block the slides. The primary antibodies used were: anti-α-SMA (product code: ab5694, Abcam, Cambridge, MA, USA), anti-CD68 (product code: ab53444, Abcam, Cambridge, MA, USA), anti-collagen I (product code: ab34710, Abcam, Cambridge, MA, USA), and anti-collagen III (product code: ab7778, Abcam, Cambridge, MA, USA). These primary antibodies were applied overnight in a refrigerator at 4°C. After washing, a secondary antibody, anti-rabbit mouse immunoglobulins (clone MR12/53, DakoDiagnostika, Hamburg, Germany) was added inside and incubated at 37°C for 30 minutes. Reaction products were visualized by incubation with diaminobenzidine (Liquid DAB+, DakoDiagnostika, Hamburg, Germany) and counterstained with hematoxylin. And then, a leica microscope (Leica DM2500, Germany) was used to measure the optical density values. We scanned 10 images for each slice (10 × 2.5 original magnification; 0.22 mm² total area per image).

Supplementary Table 1. Nutritional differences between standard diet and high-fat, high-cholesterol diet

<table>
<thead>
<tr>
<th></th>
<th>Standard diet</th>
<th>High-fat high-cholesterol diet</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total caloric value</td>
<td>16.55 MJ/kg</td>
<td>19.19 MJ/kg</td>
</tr>
<tr>
<td>Carbohydrates</td>
<td>44.70%</td>
<td>36.40%</td>
</tr>
<tr>
<td>Crude protein</td>
<td>22.10%</td>
<td>19.30%</td>
</tr>
<tr>
<td>Fat (cholesterol)</td>
<td>Minor*</td>
<td>2.74%</td>
</tr>
<tr>
<td>Other fat</td>
<td>3.00%</td>
<td>13.26%</td>
</tr>
<tr>
<td>Crude fiber</td>
<td>3.30%</td>
<td>3.50%</td>
</tr>
<tr>
<td>Crude ash</td>
<td>7.80%</td>
<td>3.20%</td>
</tr>
<tr>
<td>Others (water, etc.)</td>
<td>19.10%</td>
<td>21.60%</td>
</tr>
</tbody>
</table>

*about 0.156 mg/g diet.
**Supplementary Table 2.** NAFLD clinical research network scoring system definitions and scores

<table>
<thead>
<tr>
<th>Item</th>
<th>Definition 3</th>
<th>Time (week)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steatosis Grade</td>
<td></td>
<td>6 9 12 15 18 21 24</td>
</tr>
<tr>
<td>&lt; 33%</td>
<td>8 0 1 0 0 0 0</td>
<td></td>
</tr>
<tr>
<td>33%-66%</td>
<td>0 8 7 6 3 0 0</td>
<td></td>
</tr>
<tr>
<td>&gt; 66%</td>
<td>0 0 0 2 5 8 8</td>
<td></td>
</tr>
<tr>
<td>Microvesicular steatosis</td>
<td>Not present</td>
<td>8 8 2 0 1 0 0</td>
</tr>
<tr>
<td>Present</td>
<td>0 0 6 8 7 8 8</td>
<td></td>
</tr>
<tr>
<td>Fibrosis Stage</td>
<td></td>
<td>8 8 8 4 0 2 1 0</td>
</tr>
<tr>
<td>None</td>
<td>0 0 0 4 0 0 0 0</td>
<td></td>
</tr>
<tr>
<td>Perisinusoidal or periportal</td>
<td>0 0 0 2 1 0 0</td>
<td></td>
</tr>
<tr>
<td>Mild, zone 3, perisinusoidal</td>
<td>0 0 0 5 2 2 0</td>
<td></td>
</tr>
<tr>
<td>Moderate, zone 3, perisinusoidal</td>
<td>0 0 0 1 3 3 3</td>
<td></td>
</tr>
<tr>
<td>Portal/periportal</td>
<td>0 0 0 0 1 3 3 3</td>
<td></td>
</tr>
<tr>
<td>Bridging fibrosis</td>
<td>0 0 0 0 0 0 0 0</td>
<td></td>
</tr>
<tr>
<td>Cirrhosis</td>
<td>0 0 0 0 0 0 0 0</td>
<td></td>
</tr>
<tr>
<td>Inflammation Lobular inflammation</td>
<td>No foci</td>
<td>8 5 7 4 1 0 1 0</td>
</tr>
<tr>
<td>&lt; foci per 200 × field</td>
<td>0 3 1 4 7 8 7 8</td>
<td></td>
</tr>
<tr>
<td>&gt; 2 foci per 200 × field</td>
<td>0 0 0 0 0 0 0 0</td>
<td></td>
</tr>
<tr>
<td>Portal inflammation</td>
<td></td>
<td>8 8 3 4 2 3 5 4</td>
</tr>
<tr>
<td>None to minimal</td>
<td>0 0 5 4 6 5 3 4</td>
<td></td>
</tr>
<tr>
<td>Greater than minimal</td>
<td>0 0 5 4 6 5 3 4</td>
<td></td>
</tr>
<tr>
<td>Liver cell injury Ballooning</td>
<td>None</td>
<td>8 3 0 0 0 0 0 0</td>
</tr>
<tr>
<td>Few balloon cells</td>
<td>0 5 1 0 0 0 0 0</td>
<td></td>
</tr>
<tr>
<td>Many cells/prominent ballooning</td>
<td>0 0 7 8 8 8 8 8</td>
<td></td>
</tr>
<tr>
<td>Result</td>
<td>Steatosis</td>
<td>NASH without fibrosis</td>
</tr>
<tr>
<td>Steatosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NASH without fibrosis</td>
<td>8 8 8 4 0 2 1 0</td>
<td></td>
</tr>
<tr>
<td>NASH with fibrosis</td>
<td>0 0 0 4 0 0 0 0</td>
<td></td>
</tr>
<tr>
<td>Advanced fibrosis/cirrhosis</td>
<td>0 0 0 0 0 0 0 0</td>
<td></td>
</tr>
</tbody>
</table>

*(n = 8, score means the number of animals with described symptom at each time point. NAFLD: nonalcoholic fatty liver disease; NASH: nonalcoholic steatohepatitis).*

**Supplementary Table 3.** Biochemical characteristics of control group and model groups during the first 9 weeks HFHCD induction

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>3 weeks</th>
<th>6 weeks</th>
<th>9 weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALT (U/L)</td>
<td>70.44 ± 4.03</td>
<td>73.80 ± 9.93</td>
<td>88.00 ± 15.80**</td>
<td>77.71 ± 21.26</td>
</tr>
<tr>
<td>AST (U/L)</td>
<td>164.38 ± 17.85</td>
<td>192.67 ± 35.42*</td>
<td>179.25 ± 29.26</td>
<td>193.86 ± 31.36*</td>
</tr>
<tr>
<td>GLU (mmol/L)</td>
<td>4.55 ± 0.40</td>
<td>6.28 ± 1.13**</td>
<td>6.56 ± 0.56**</td>
<td>7.48 ± 1.55**</td>
</tr>
<tr>
<td>TG (mmol/L)</td>
<td>1.11 ± 0.43</td>
<td>1.95 ± 0.40**</td>
<td>1.51 ± 0.43*</td>
<td>0.48 ± 0.14**</td>
</tr>
<tr>
<td>CHO (mmol/L)</td>
<td>2.66 ± 0.70</td>
<td>10.42 ± 2.47**</td>
<td>7.89 ± 2.89**</td>
<td>4.75 ± 0.87**</td>
</tr>
</tbody>
</table>

*P < 0.05, **P < 0.01.

**Supplementary Table 4.** Body weight of control group and model groups during the first 9 weeks HFHCD induction

<table>
<thead>
<tr>
<th>Body weight (g)</th>
<th>Control</th>
<th>3 weeks</th>
<th>6 weeks</th>
<th>9 weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body weight</td>
<td>41.51 ± 3.71</td>
<td>47.89 ± 2.93</td>
<td>54.16 ± 5.02</td>
<td></td>
</tr>
<tr>
<td>Model</td>
<td>40.13 ± 6.20</td>
<td>58.93 ± 6.04**</td>
<td>64.64 ± 5.67**</td>
<td></td>
</tr>
</tbody>
</table>

**P < 0.01.**